ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Recordati to acquire EUSA Pharma to expand rare disease products portfolio
December 06, 2021Italian company Recordati has signed an agreement to acquire EUSA Pharma in a deal worth about $848.9m (€750m) to expand its rare disease products portfolio. -
Recordati acquires rights to Signifor and osilodrostat from Novartis
July 17, 2019Recordati has agreed to acquire the global rights to two of Novartis’ medicines, Signifor and osilodrostat, for the treatment of patients suffering from endocrine diseases. -
CVC Capital revs up rare disease ambitions with $3.5B Recordati buyout
July 03, 2018Recordati has finally sealed a sale. Private equity player CVC Capital Partners said (PDF) Friday it would drop €3.03 billion
Pharma Sources Insight January 2025
